Jules Bordet Institute

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 1939-01-01

Employees: 1K

Market Cap: -

Website: http://www.bordet.be

Clinical Trials

Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

Phase 2

Withdrawn

Conditions: Non Small Cell Lung Cancer
Brain Metastasis
Breast Cancer

Interventions: Drug: Cabazitaxel
Procedure: Contrast-enhanced whole brain MRI

First Posted Date: 2013-07-31

Last Posted Date: 2014-07-24

Lead Sponsor: Jules Bordet Institute

Registration Number: NCT01913067

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Denosumab

First Posted Date: 2013-05-30

Last Posted Date: 2018-11-27

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 27

Registration Number: NCT01864798

Locations: 🇦🇺
Royal Melbourne Hospital, Victoria, Australia
🇧🇪
Institute Jules Bordet, Brussels, Belgium
🇧🇪
Hopital Erasme, Brussels, Belgium

and more 3 locations

Randomized Phase III of PRRT Versus Interferon

Phase 3

Withdrawn

Conditions: Gastro-intestinal Neuroendocrine Tumors

Interventions: Drug: Interferon alpha-2b
Drug: 177Lu-DOTATATE

First Posted Date: 2013-05-23

Last Posted Date: 2016-04-05

Lead Sponsor: Jules Bordet Institute

Registration Number: NCT01860742

Locations: 🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪
Jules Bordet Institute, Brussels, Belgium

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

Phase 1

Completed

Conditions: Metastatic Gastric Cancers
Metastatic Colorectal Cancers
Metastatic Oesophageal Cancers
Metastatic Pancreatic Cancers
Metastatic Biliary Cancers
Metastatic Breast Cancers

Interventions: Drug: aflibercept
Drug: Capecitabine

First Posted Date: 2013-05-01

Last Posted Date: 2018-01-31

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 37

Registration Number: NCT01843725

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

Phase 3

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumors

Interventions: Drug: Intravenous injection of 177Lu-octreotate

First Posted Date: 2013-04-29

Last Posted Date: 2022-11-10

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 37

Registration Number: NCT01842165

Locations: 🇧🇪
Jules Bordet Institute, Brussels, Belgium

Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients

Phase 1

Completed

Conditions: Peritoneal Carcinomatosis
Ovarian Cancer

Interventions: Drug: iv injection of ICG

First Posted Date: 2013-04-18

Last Posted Date: 2014-10-15

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 10

Registration Number: NCT01834469

Locations: 🇧🇪
Jules Bordet Institute, Brussels, Belgium

Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Phase 1

Completed

Conditions: Ovarian Carcinoma
Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma

Interventions: Procedure: HIPEC

First Posted Date: 2012-10-18

Last Posted Date: 2016-02-24

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 19

Registration Number: NCT01709487

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Hopital de la Citadelle, Liège, Belgium

Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver

Phase 2

Terminated

Conditions: Hepatocellular Carcinoma
Liver Cirrhosis

Interventions: Device: Sirsphere trans-arterial radioembolization

First Posted Date: 2012-09-18

Last Posted Date: 2015-07-01

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 10

Registration Number: NCT01686880

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Erasme Hosptial, Brussels, Belgium

Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia

Phase 2

Conditions: Breast Cancer

Interventions: Drug: GCSF administration on days 8 and 12 after chemotherapy

First Posted Date: 2012-08-07

Last Posted Date: 2015-01-06

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 142

Registration Number: NCT01658956

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium

Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Other: FDG PET-CT
Other: Diffusion MRI
Other: Blood samples (plasma preparation and CTC)

First Posted Date: 2012-05-04

Last Posted Date: 2021-10-26

Lead Sponsor: Jules Bordet Institute

Target Recruit Count: 53

Registration Number: NCT01591590

Locations: 🇧🇪
Jules Bordet Institute, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy